

Session VII: Policies for Workforce Sustainability and Future-Proofing

Elizabeth Ofili, MD, MPH, FACC
Professor of Medicine (Cardiology)
Morehouse School of Medicine

Preparing the Future Workforce in Drug Research and Development-A Workshop

October 16-17, 2023

Washington DC

National Academies Forum on Drug Discovery, Development, and Translation

in Collaboration with

The Roundtable on Black Men and Black Women in Science, Engineering, and Medicine

Disclosures

Elizabeth O. Ofili, MD, MPH, FACC

- **Grant/Research support:** National Institutes of Health
- **Advisory Board/Consultant:** AMGEN; NIH All of Us Research Program.
- **Patent:** A System and Method for Chronic Illness Care (Ofili et al. Patent # US 8,234,131 B2) issued in 2012
- **AccuHealth Technologies** Small Business Innovation Research (SBIR) Award Number: 1R44TR003832-01 April 1, 2021-March 31, 2024
- **Founder and Chief Executive Officer:** AccuHealth Technologies Inc.

Session VII Objectives

1. Explore policies and procedures that could be implemented to ensure a more person-centered, culturally aware drug R&D workforce in 2030
2. Consider guiding principles for different stakeholders to support and enable a more person-centered, culturally aware drug R&D workforce

Implications for Future Workforce Policies: The current evidence-based medicine (EBM) pyramid represents the tip of the iceberg and barely provides enough shallow evidence to care for a generic patient

naturemedicine

Explore content ▾ About the journal ▾ Publish with us ▾


[nature](#) > [nature medicine](#) > [perspectives](#) > article

Perspective | Published: 16 January 2023

The next generation of evidence-based medicine


[Vivek Subbiah](#) ✉

Nature Medicine 29, 49–58 (2023) | [Cite this article](#)



Vivek Subbiah; Nature Medicine 29, 49-58(2023)

The Patient as the Center of the Clinical Trial Universe in the Clinical Research Enterprise & Stakeholders for Workforce Policy



Vivek Subiah; Nature Medicine 29, 49-58(2023)

Late Breaking Clinical Trial: Health 360x Registry-Equitable Access to Point of Care Decentralized Clinical Trials

ACC.23
TOGETHER WITH
WCC

ADVANCING **CARDIOVASCULAR CARE** FOR ALL



Dear Elizabeth O. Ofili MBBS, MPH, FACC:

[Congratulations!](#)

We are pleased to confirm that your late-breaking clinical trial (LBCT) or featured clinical research (FCR) abstract submission, "Health 360x Registry: Equitable Access To Point Of Care Decentralized Clinical Trials" (control number 20846), has been accepted for presentation at ACC.23/WCC, March 4-6, live in New Orleans, Louisiana.


Presenting your research at the Annual Scientific Session represents a critical contribution to the evolving science and innovative strategies that are central to the experience at ACC.23/WCC. The selection process was highly competitive this year.

Ofili EO et al. Health360x Registry Equitable Access to Point Of Care Decentralized Clinical Trials-Late Breaking Clinical Trial: American College of Cardiology Annual Scientific Conference, 2023; 23-LBCT-20846-ACC

AccuHealth Technologies Small Business Innovation Research (SBIR) Award Number: 1R44TR003832-01 April 1, 2021-March 31, 2024 (National Center for Advancing Translational Science at NIH)

The content of the abstract is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

Remote Approaches/Decentralized Clinical trials During COVID-19: Implications for R&D Workforce Policy



Levy presentation, January 26, 2021; National Academies of Sciences, Engineering, and Medicine. 2022. Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop. Washington, DC: The National Academies Press. <https://doi.org/10.17226/26349>.



Research Centers at Minority Institutions: A Consortium of Twenty two NIH funded Institutions and a Coordinating Center for Workforce Diversity and Inclusive Excellence

Visit www.rcmi-cc.org



The RCMI-CC is supported by grant number U24MD015970 from the [National Institute on Minority Health and Health Disparities](http://www.nih.gov/), National Institutes of Health.

RCMI Consortium of 22 independently funded U 54 Centers and a Coordinating Center (NIMHD)



- 1300 Scientists in health disparities research
- 10,000 Articles and papers published by RCMI Investigators
- 1000+ R01 awards
- Visit www.rcmi-cc.org

Ofili EO et al. The Research Centers in Minority Institutions (RCMI) Consortium: A Blueprint for Inclusive Excellence. Int. J. Environ. Res. Public Health 2021, 18, 6848. [https:// doi.org/10.3390/ijerph18136848](https://doi.org/10.3390/ijerph18136848)

NIMHD=National Institute on Minority Health and Health Disparities at NIH

RCMI Collaborative Biomedical Research and Training Infrastructure




RESEARCH CENTERS IN MINORITY INSTITUTIONS



RCMI

CTSA Program hubs (NCATS) collaborate with each other to develop, demonstrate and disseminate innovative methods and technologies to turn scientific discoveries into clinical advances more efficiently



NCATS=National Center for Advancing Translational Science at NIH



We provide resources for:


RESEARCHERS


SCHOLARS AND TRAINEES



COMMUNITY

georgiactsa.org



We provide resources for:


RESEARCHERS



Georgia Clinical and Translational Science Alliance (Georgia CTSA): Emory University; Morehouse School of Medicine; Georgia Institute of Technology; University of Georgia And Partnering Health Systems. Visit www.georgiactsa.org

All of Us Research Program: Model of Participants as Research Partners




Patient Perceptions About Their Physician

A Positive words



B Negative words



Singletary B. et al. Patient Perceptions About Their Physician in 2Words

The Good, the Bad, and the Ugly. JAMA Surgery December 2017 Volume 152, Number 12:1169

Policies and Procedures to Ensure A More Person Centered Culturally Aware R&D Workforce

1. Person-Centeredness
 - Incentivize participants as research partners/citizen scientists
 - Digital health innovation: participants collect and share research data (PROs)
2. Research Awarding Federal Agencies (e.g. NIH; FDA; NSF; DoD; CDC)
 - Prioritize Metrics for Inclusive Excellence in R&D Workforce Programs: e.g. CTSA/RCMI
 - Incentivize community-centered partnerships and industry collaborations for sustainable R&D workforce at the Point of Care e.g, Community and Rural practices; Home Health
3. Clinical Trial Physicians and multidisciplinary research teams: Promotion and Tenure policies
4. Research Coordinators: Incentivize pipeline for training and certification: partnerships with HBCUs; Community Colleges; Culturally Aware Mentorship in research training/simulation
5. Policies to support the growing role of data scientists in clinical trial R&D workforce
6. Research Innovation and Regulatory policies for Health Related Data and Registries
 - Data Governance-Real World Evidence Data for Drug approval and Post-market surveillance
 - Workforce Automation- Artificial Intelligence/Machine Learning and Research Ethics

THANK YOU!!



www.msm.edu

Leading the Creation and Advancement of Health Equity

#1 in Social Mission among US medical schools (Annals of Internal Medicine, June 2010)